Immunohistochemistry (IHC) Market Forecast Insights: The Road To $4.47 Billion By 2030
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Immunohistochemistry (IHC) Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The immunohistochemistry (ihc) market has experienced substantial expansion in recent years. Its valuation is projected to increase from $2.76 billion in 2025 to $3.05 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.3%. The drivers behind this past growth include the escalating utilization of ihc in cancer diagnostics, the expansion of hospital pathology laboratories, improved availability of monoclonal antibodies, a rise in the adoption of tissue-based diagnostics, and an increase in clinical research activities.
The market size for immunohistochemistry (IHC) is projected to experience swift expansion over the coming years. This market is forecast to reach $4.47 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 10.1%. Key factors contributing to this growth during the projection period include the escalating demand for precision oncology diagnostics, the growing embrace of AI-enabled pathology analysis, the broadening of biomarker-driven drug development, the expanding application of multiplex tissue profiling, and increased financial commitments towards advanced pathology infrastructure. Significant trends anticipated for the forecast timeframe encompass the increasing deployment of automated IHC staining systems, a rise in the utilization of multiplex IHC techniques, the progressing integration of digital pathology platforms, the widening scope of companion diagnostic applications, and a heightened emphasis on high-specificity antibodies.
Get A Free Sample Report With In-Depth Market Insights:
Immunohistochemistry (IHC) Market Growth Factors Behind Sustained Expansion
The increasing demand for personalized medicines is projected to boost the growth of the immunohistochemistry (IHC) market moving forward. Personalized medicine is a healthcare strategy that involves adapting medical decisions, practices, interventions, and products specifically for each patient based on their unique genetic, environmental, and lifestyle attributes. Immunohistochemistry (IHC) plays a vital role in personalized medicine, as it is utilized to detect specific protein markers that can aid in accurate tumor classification and diagnosis. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit research organization, reported that personalized medicines comprised more than one-third of new approvals by the US Food and Drug Administration in 2023. In the same year, the FDA gave approval to 16 new personalized treatments for rare-disease patients, which was an increase from 6 in 2022. Thus, the escalating demand for personalized medicines is a significant factor driving the expansion of the immunohistochemistry (IHC) market.
Immunohistochemistry (IHC) Market Segment Landscape: Which Areas Lead Development?
The immunohistochemistry (ihc) market covered in this report is segmented –
1) By Product: Antibodies, Equipment, Reagents, Kits
2) By Applications: Diagnostics, Drug Testing, Other Applications
3) By End-Users: Hospitals And Diagnostic Laboratories, Research Institutes, Other End-Users
Subsegments:
1) By Antibodies: Primary Antibodies, Secondary Antibodies, Conjugated Antibodies
2) By Equipment: IHC Staining Systems, Slide Scanners, Microscopes
3) By Reagents: Detection Reagents, Blocking Reagents, Mounting Media
4) By Kits: Pre-prepared IHC Kits, Multiplex IHC Kits, Specialty Kits
Immunohistochemistry (IHC) Market Industry Trends Fueling Future Revenue Growth
Major companies operating in the immunohistochemistry (IHC) market are concentrating on enhancing diagnostic accuracy by employing innovative technologies and high-quality reagents, thereby improving the effectiveness of tissue analysis in diverse clinical and research applications. The Neoflex multiomics mass spectrometry imaging (MSI) system stands as an advanced imaging platform engineered for meticulous tissue analysis, enabling researchers to transition from initial discovery phases to clinical implementations using high-resolution mass spectrometry techniques, particularly for the spatial mapping of biomolecules within tissues. For instance, in June 2024, Bruker Corporation, a US-based company engaged in the development and manufacture of scientific instruments and analytical and diagnostic solutions, unveiled its matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF/TOF) Neoflex Imaging Profiler, intended for mass spectrometry-based tissue imaging. The Neoflex multiomics mass spectrometry imaging (MSI) system addresses the necessity of advancing from discovery imaging to clinical tissue research. It incorporates Bruker’s 10-kHz smartbeam 3D laser, includes enhanced imaging detectors, and supports OME-TIFF file output when utilized with SCiLS Scope software.
Immunohistochemistry (IHC) Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the immunohistochemistry (ihc) market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche AG, Merck Group, Danaher Corporation, PerkinElmer Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Bio SB Inc., Agilent Technologies Inc., Abcam plc, Takara Bio Inc., Biocare Medical LLC, Bio-Genex Laboratories, Diagnostic BioSystems Inc., PHC Holdings Corporation, Leica Biosystems, Vector Laboratories, Ionpath Inc., Reveal Biosciences, Akrivis Technologies Private Limited, LifeSpan BioSciences Inc., Enzo Life Sciences Inc., Epitomics Inc., GenScript Biotech
View The Full Immunohistochemistry (IHC) Market Report:
Immunohistochemistry (IHC) Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the immunohistochemistry (IHC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the immunohistochemistry (IHC) market report during the forecast period. The regions covered in the immunohistochemistry (ihc) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
